BOURLA ALBERT 4

What Happened
Albert Bourla, Chairman & CEO of Pfizer Inc., was granted 21 derivative units (each representing one phantom share) on 2026-03-31 at an attributed value of $28.08 per unit, totaling roughly $590. The award is reported as an acquisition (grant) under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-01 (timely filing).
• Units/Amount: 21 units @ $28.08 each = $590 (derivative units / phantom shares).
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes:
  • F1: Each unit represents one phantom share of common stock.
  • F2: Units were acquired under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash following the reporting person's separation from service; they may be transferred by the reporting person into an alternative investment account at any time.
• Transaction type code: A = Award/Grant (derivative).

Context
This was a grant of phantom (derivative) units, not an issuance of actual common stock; they will be settled in cash upon separation from service unless transferred into an alternative investment account. The economic value reported is modest ($590) relative to typical executive holdings and does not, by itself, indicate a change in insider sentiment.